Clinical Treatment Efficacy of Total Thyroidectomy Combined with Radioactive Iodine on Treatment of Thyroid Cancer and Its Effect on the Quality of Life of Patients
Background: To investigate the treatment efficacy of radioactive iodine therapy on patients after total thyroidectomy and its effect on the quality of life.
Methods: A retrospective analysis of clinical data of 120 thyroid cancer patients admitted to Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, China from February 2014 to February 2017 was performed. According to different treatment methods, they were divided into observation group of 62 cases and control group of 58 cases. Both groups were treated with total thyroidectomy. The control group was treated with anti-infection and prevention of complications after operation, the observation group with radioactive iodine therapy. Treatment efficacy, quality of life score, recurrent laryngeal nerve injury and postoperative survival rate were compared between the two groups.
Results: The total effective rate of treatment in the test group was 98.39%, significantly higher than 72.41% in the control group, with a statistically significant difference (P<0.05). Compared with the control group, the fatigue score of the test group was lower, but the score in the area of emotion function and the overall health status score were higher, with a statistically significant difference (P<0.05). There was no significant difference in the recurrent laryngeal nerve injury between the two groups of patients. The postoperative survival rate of the test group of patients was 96.77%, significantly higher than 86.21% of the control group.
Conclusion: The effect of radioactive iodine therapy after total thyroidectomy is remarkable, which can significantly improve the clinical treatment efficacy and postoperative quality of life of patients, worthy of clinical application.
2. Lee HS, Park C, Kim SW, Song JW, Chun BK, Park TJ, Hong JC, Lee KD (2016). Primary tumour characteristics predict the invasiveness of lymph node metastases in papillary thyroid carcinoma patients. J Laryngol Otol, 130: 302-308.
3. Sheils O (2005). Molecular classification and biomarker discovery in papillary thyroid carcinoma. Expert Rev Mol Diagn, 5: 927-946.
4. Tang W, Huang C, Tang C, Xu J, Wang H (2016). Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. Onco Targets Ther, 9: 455-460.
5. Maxwell J, Howe JR (2017). Total Thyroidectomy. Operative Dictations in General and Vascular Surgery. Springer International Publishing.
6. Cho JN, Park WS, Min SY (2016). Predictors and risk factors of hypoparathyroidism after total thyroidectomy. Int J Surg, 34: 47-52.
7. Shin YW, Choi YM, Kim HS, et al (2016). Diminished Quality of Life and Increased Brain Functional Connectivity in Patients with Hypothyroidism After Total Thyroidectomy. Thyroid, 26: 641-649.
8. Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW (2012). Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann Surg Oncol, 19: 4217-4222.
9. Reiners C, Dietlein M, Luster M (2008). Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab, 22: 989-1007.
10. Espiritu RP, Stan MN (2008). Rhabdomyolysis after withdrawal of thyroid hormone in a patient with papillary thyroid cancer. Endocr Pract, 14: 1023-1026.
11. Ciftci F, Sakalli E, Abdurrahman I (2015). Total versus bilateral subtotal thyroidectomy for benign multi-nodular goiter. Int J Clin Exp Med, 8: 4596-4600.
12. Kus LH, Hopman WM, Witterick IJ, Freeman JL (2017). Quality-of-life outcomes in Graves disease patients after total thyroidectomy. Ear Nose Throat J, 96: E8-e15.
13. Sipos JA (2009). Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid, 19: 1363-1372.
14. Rajkovaca Z, Kovacevic P, Stanetic M, Ristic S (2012). [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma]. Vojnosanit Pregl, 69: 941-946. [Article in Serbian].
15. Calo PG, Conzo G, Raffaelli M, et al CP (2017). Total thyroidectomy alone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study. Eur J Surg Oncol, 43: 126-132.
16. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV (2011). Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf), 75: 544-554.
17. Schmutzler C, Kohrle J (2000). Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid, 10: 393-406.
18. Li H, Du XM, Feng Z, Feng JX (2017). Effects of Different Doses~(131)I Thyroidectom Treatment on Salivary Gland Function and Life Quality of Patients with Thyroid Carcinoma. Medical & Pharmaceutical Journal of Chinese Peoples Liberation Army.
19. Lim ST, Jeong HJ, Chung MJ, Yim CY, Sohn MH (2008). Malignant struma ovarii demonstrated on post-therapy radioiodine scan after total thyroidectomy for papillary thyroid cancer. Clin Nucl Med, 33: 429-431.
20. Hong CM, Lee WK, Jeong SY, Lee SW, Ahn BC, Lee J (2014). Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. Nucl Med Commun, 35: 1119-1126.
21. Amoako-Tuffour Y, Graham ME, Bullock M, Rigby MH, Trites J, Taylor SM, Hart RD (2017). Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report. Thyroid Res, 10: 8.
22. Rivkees SA, Mazzaferri EL, Verburg FA, etval (2011). The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev, 32: 798-826.